AngioDynamics Highlights Growth Strategy at J.P. Morgan Conference

The latest update is out from AngioDynamics ( (ANGO) ).

On January 14, 2026, President and CEO James Clemmer presented AngioDynamics’ growth strategy and product portfolio at the J.P. Morgan 44th Annual Healthcare Conference, highlighting the company’s transition since 2020 into a more growth-focused MedTech business with a higher-margin mix, improved operations, and a robust pipeline in cardiovascular and prostate care. The presentation underscored the company’s positioning in large and underpenetrated U.S. markets—such as peripheral artery disease, venous thromboembolism and prostate care—citing strong adoption of its Auryon peripheral artery disease platform, expanding reimbursement, and FDA-cleared AlphaVac mechanical thrombectomy system for pulmonary embolism following the APEX-AV pivotal study, which showed a significantly greater reduction in clot burden than competing technologies, reinforcing AngioDynamics’ bid for sustained profitable growth and a stronger competitive standing in interventional cardiovascular care.

The most recent analyst rating on (ANGO) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.

Spark’s Take on ANGO Stock

According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.

The score is mainly supported by improved operating momentum and raised FY2026 guidance from the latest earnings call, plus a very conservative balance sheet with minimal debt. These positives are offset by weak current financial performance (ongoing losses and negative TTM operating/free cash flow) and bearish technicals with the stock trading below key moving averages.

To see Spark’s full report on ANGO stock, click here.

More about AngioDynamics

AngioDynamics is a medical technology company focused on minimally invasive devices for cardiovascular disease and cancer, with a synergistic portfolio targeting major U.S. markets including prostate care, peripheral artery disease and venous thromboembolism. The company has shifted its sales mix toward higher-growth MedTech offerings between fiscal 2020 and 2025, strengthened its financial position, accelerated innovation through R&D and strategic M&A, and is building out its commercial presence in cardiovascular and prostate segments to capture expanding total addressable markets.

Average Trading Volume: 571,271

Technical Sentiment Signal: Sell

Current Market Cap: $419.6M

For an in-depth examination of ANGO stock, go to TipRanks’ Overview page.